Gapping up
In reaction to strong earnings/guidance: ARNA +26.3%, IMPV +13.7%, AXTI +11.6%, GDOT +8.4%, TNDM +8.1%, SKUL +7%, SWIR +6.6%, LNKD +6.5%, BEAT +5.6%, (light volume), SYNA +5.2%, KCG +5.1%, EXPE +3.8%, IRE +3.7%, MHK +3.2%, AHS +3.1%, DATA +2.3%, WU +1.9%, (light volume), PG +1.8%, MCHP +1.3%, (light volume), CYH +1%, ONNN +0.9%, CTRX+0.9%, AVD +0.7%, (light volume), LNG +0.2%, (light volume), AIV +0.1%, (saw late move higher following early earnings release), .
M&A news: BYI +33.5% (Scientific Games to acquire Bally Technologies in transaction valued at $5.1 billion), IBCA +10.3% (Intervest Bancshares Corp to be acquired by Bank of the Ozarks in an all-stock transaction).
Select oil/gas related names showing strength: STO +0.8%, TOT +0.6%.
Other news: ARRY +8.5% (received orphan drug designation status for binimetinib for the treatment of ovarian cancer), SRPT +2.9% (announces appointment of John Hodgman as interim chairman; also initiated with an Outperform at Oppenheimer), JD +2.5% (trading higher following positive MadMoney mention), FNMA +1.4% (releases June 2014 monthly summary; Book of Business decreased at a compound annualized rate of 1.7% in June), VRTX +0.7% (light volume; receives European approval for KALYDECO (ivacaftor) in eight non-G551D gating mutations; KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations )
Analyst comments: RNA +3.9% (light volume, initiated with an Outperform at Oppenheimer), DV +0.3% (DeVry upgraded to Buy from Hold at Stifel)
M&A news: BYI +33.5% (Scientific Games to acquire Bally Technologies in transaction valued at $5.1 billion), IBCA +10.3% (Intervest Bancshares Corp to be acquired by Bank of the Ozarks in an all-stock transaction).
Select oil/gas related names showing strength: STO +0.8%, TOT +0.6%.
Other news: ARRY +8.5% (received orphan drug designation status for binimetinib for the treatment of ovarian cancer), SRPT +2.9% (announces appointment of John Hodgman as interim chairman; also initiated with an Outperform at Oppenheimer), JD +2.5% (trading higher following positive MadMoney mention), FNMA +1.4% (releases June 2014 monthly summary; Book of Business decreased at a compound annualized rate of 1.7% in June), VRTX +0.7% (light volume; receives European approval for KALYDECO (ivacaftor) in eight non-G551D gating mutations; KALYDECO is the first medicine to treat the underlying cause of CF in people with specific non-G551D gating mutations )
Analyst comments: RNA +3.9% (light volume, initiated with an Outperform at Oppenheimer), DV +0.3% (DeVry upgraded to Buy from Hold at Stifel)